NCT03727451View on ClinicalTrials.gov

A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 30, 2019

Primary Completion Date

September 7, 2021

Study Completion Date

June 15, 2022

Conditions
Pulmonary HypertensionPulmonary FibrosisSarcoidosis, Pulmonary
Interventions
COMBINATION_PRODUCT

iNO

inhaled nitric oxide

Trial Locations (6)

19140

Temple University, Philadelphia

22042

Inova Heart and Lung Vascular Institute, Falls Church

33125

University of Miami, Miami

37232

Vanderbilt University Medical Center, Nashville

45219

University of Cincinnati, Cincinnati

98195

University of Washington Medical Center, Seattle

All Listed Sponsors
lead

Bellerophon

INDUSTRY

NCT03727451 - A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis | Biotech Hunter | Biotech Hunter